Amyotrophic lateral sclerosis (ALS) is an incurable disease that arises from the progressive loss of motoneurons. Even when caused by a single gene defect, as in the case of mutations in the enzyme Cu-Zn superoxide dismutase (SOD1), ALS is the result of a complex cascade that involves crosstalk among motoneurons, glia and muscles, and evolves through the action of converging toxic mechanisms. Transgenic rodents that express human mutant SOD1 and develop a progressive paralytic disease are widely used to screen potential therapeutics. Treatments that interfere with a specific event in the neurotoxic cascade have been reported to produce a modest increase in rodent lifespan. Multi-intervention approaches, including novel methods to intercept the damage and to deliver molecules to vulnerable cells, have recently been shown to be more effective. Thus, new avenues for promising therapeutic approaches can be derived from multidrug treatments and/or the delivery of growth factors by viral vectors, in combination with exercise and/or diet regimens.

Carri', M.t., Grignaschi, G., Bendotti, C. (2006). Targets in ALS: designing multidrug therapies. TRENDS IN PHARMACOLOGICAL SCIENCES, 27(5), 267-273 [10.1016/j.tips.2006.03.009].

Targets in ALS: designing multidrug therapies

CARRI', MARIA TERESA;
2006-05-01

Abstract

Amyotrophic lateral sclerosis (ALS) is an incurable disease that arises from the progressive loss of motoneurons. Even when caused by a single gene defect, as in the case of mutations in the enzyme Cu-Zn superoxide dismutase (SOD1), ALS is the result of a complex cascade that involves crosstalk among motoneurons, glia and muscles, and evolves through the action of converging toxic mechanisms. Transgenic rodents that express human mutant SOD1 and develop a progressive paralytic disease are widely used to screen potential therapeutics. Treatments that interfere with a specific event in the neurotoxic cascade have been reported to produce a modest increase in rodent lifespan. Multi-intervention approaches, including novel methods to intercept the damage and to deliver molecules to vulnerable cells, have recently been shown to be more effective. Thus, new avenues for promising therapeutic approaches can be derived from multidrug treatments and/or the delivery of growth factors by viral vectors, in combination with exercise and/or diet regimens.
mag-2006
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore BIO/10 - BIOCHIMICA
English
Con Impact Factor ISI
Drug Therapy, Combination; Superoxide Dismutase; Drug Delivery Systems; Animals; Amyotrophic Lateral Sclerosis; Humans; Disease Models, Animal; Mice; Stem Cell Transplantation
Carri', M.t., Grignaschi, G., Bendotti, C. (2006). Targets in ALS: designing multidrug therapies. TRENDS IN PHARMACOLOGICAL SCIENCES, 27(5), 267-273 [10.1016/j.tips.2006.03.009].
Carri', Mt; Grignaschi, G; Bendotti, C
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/38867
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 51
  • ???jsp.display-item.citation.isi??? 42
social impact